Storia in 2 fonti

Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)

Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.

Raccontata da

pharmaceutical-technology.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mesi fa

Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)

Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.

originale

pharmaceutical-technology.com1 mesi fa

Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide excluding Korea.

Leggi questa versione →

Timeline cronologica

lunedì 1 giugno 2026·pharmaceutical-technology.com
Lilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide
Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate,…
lunedì 1 giugno 2026·benzinga.com
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.